481 related articles for article (PubMed ID: 30637364)
1. Analysis of
Okamura R; Boichard A; Kato S; Sicklick JK; Bazhenova L; Kurzrock R
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30637364
[TBL] [Abstract][Full Text] [Related]
2. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
Zhao X; Kotch C; Fox E; Surrey LF; Wertheim GB; Baloch ZW; Lin F; Pillai V; Luo M; Kreiger PA; Pogoriler JE; Linn RL; Russo PA; Santi M; Resnick AC; Storm PB; Hunger SP; Bauer AJ; Li MM
JCO Precis Oncol; 2021; 1():. PubMed ID: 34036219
[TBL] [Abstract][Full Text] [Related]
3. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
4.
Gambella A; Senetta R; Collemi G; Vallero SG; Monticelli M; Cofano F; Zeppa P; Garbossa D; Pellerino A; Rudà R; Soffietti R; Fagioli F; Papotti M; Cassoni P; Bertero L
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979374
[TBL] [Abstract][Full Text] [Related]
5. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
[TBL] [Abstract][Full Text] [Related]
6. GISTs with
Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101
[TBL] [Abstract][Full Text] [Related]
7. NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma.
Wang Y; Long P; Wang Y; Ma W
Front Oncol; 2020; 10():593578. PubMed ID: 33330081
[TBL] [Abstract][Full Text] [Related]
8. Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas.
Stravodimou A; Voutsadakis IA
World J Clin Oncol; 2022 Feb; 13(2):135-146. PubMed ID: 35316931
[TBL] [Abstract][Full Text] [Related]
9. A review of NTRK fusions in cancer.
Manea CA; Badiu DC; Ploscaru IC; Zgura A; Bacinschi X; Smarandache CG; Serban D; Popescu CG; Grigorean VT; Botnarciuc V
Ann Med Surg (Lond); 2022 Jul; 79():103893. PubMed ID: 35860155
[TBL] [Abstract][Full Text] [Related]
10. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
11. Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project.
Bridgewater J; Jiao X; Parimi M; Flach C; Stratford J; Kamburov A; Schmitz AA; Zong J; Reeves JA; Keating K; Bruno A; Fellous M; Pereira MB; Bazhenova L
Cancer Treat Res Commun; 2022; 33():100623. PubMed ID: 36041373
[TBL] [Abstract][Full Text] [Related]
12. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
13. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
Forschner A; Forchhammer S; Bonzheim I
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
[TBL] [Abstract][Full Text] [Related]
14. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.
Westphalen CB; Krebs MG; Le Tourneau C; Sokol ES; Maund SL; Wilson TR; Jin DX; Newberg JY; Fabrizio D; Veronese L; Thomas M; de Braud F
NPJ Precis Oncol; 2021 Jul; 5(1):69. PubMed ID: 34285332
[TBL] [Abstract][Full Text] [Related]
15. Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy.
Vanoli F; Herviou L; Tsuda Y; Sung P; Xie Z; Fishinevich E; Min SS; Mallen W; de Wardin HT; Zhang Y; Jasin M; Antonescu CR
Oncogenesis; 2023 Feb; 12(1):8. PubMed ID: 36801905
[TBL] [Abstract][Full Text] [Related]
16. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
[TBL] [Abstract][Full Text] [Related]
17. NTRK point mutations and their functional consequences.
Rogers C; Morrissette JJD; Sussman RT
Cancer Genet; 2022 Apr; 262-263():5-15. PubMed ID: 34972036
[TBL] [Abstract][Full Text] [Related]
18. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Farago AF; Taylor MS; Doebele RC; Zhu VW; Kummar S; Spira AI; Boyle TA; Haura EB; Arcila ME; Benayed R; Aisner DL; Horick NK; Lennerz JK; Le LP; Iafrate AJ; Ou SI; Shaw AT; Mino-Kenudson M; Drilon A
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30215037
[TBL] [Abstract][Full Text] [Related]
20. Detection of
Koopman B; Kuijpers CCHJ; Groen HJM; Timens W; Schuuring E; Willems SM; van Kempen LC
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
